📰 Planegg News
Page 36 - Planegg News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Planegg. Real-time updates on events, politics, business and more.
April 28, 2022
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / April 28, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the first quarter 2022 on May 4, 2022 at 10:00 pm CEST (9:00 pm GMT; 4:00 pm EDT).MorphoSys'
April 28, 2022
DGAP-News: MorphoSys AG / Key word: Quarter Results Invitation to MorphoSys First Quarter 2022 Financial Results Conference Call on May 5, 2022 28.04.2022 / 22:03 The issuer...
March 23, 2022
DGAP-News: MorphoSys AG / Key word(s): Miscellaneous22.03.2022 / 21:01 The issuer is solely responsible for the content of this announcement.Media ReleaseMorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed...
March 22, 2022
22.03.2022 - DGAP-News: MorphoSys AG / Key word(s): Miscellaneous MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with r/r DLBCL 22.03.2022 / 21:01 The issuer ... Seite 1
March 22, 2022
MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell LymphomaMinjuvi
March 17, 2022
MOR earnings call for the period ending December 31, 2021.
March 16, 2022
Monjuvi U.S. net product sales of US$ 23.6 million (€ 20.5 million) for the fourth quarter and US$ 79.1 million (€ 66.9 million) for the full year 2021 Pipeline advances: enrollment progressing across
March 16, 2022
DGAP-News: MorphoSys AG / Key word: Annual Report MorphoSys AG Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update 16.03.2022 / 21:01 The... | March 16, 2022
March 15, 2022
BOSTON, MA / ACCESSWIRE / March 15, 2022 / MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG (FSE:MOR)(NASDAQ:MOR), announced today that the National Comprehensive Cancer Network(R) (NCCN)
March 15, 2022
DGAP-News: MorphoSys AG / Key word(s): Miscellaneous15.03.2022 / 21:01 The issuer is solely responsible for the content of this announcement.Media ReleaseNational Comprehensive Cancer Network(R) Updates Designation of Monjuvi(R) (tafasitamab-cxix) to Preferred Regimen in its Clinical Practice Guidelines in Oncology...